Roche Holding stock heads into the open after a 0.8% slide
Published on 09/16/2026 at 07:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Roche Holding stock closed at 358.40 CHF on the SIX Swiss Exchange on September 15, 2026, down 0.8% from the previous session’s close per SIX data cited by finanzen.ch. The move came in a softer Swiss equity market, with the SMI ending the same session 0.57% lower at 13,799.44 points.
September 15, 2026 in numbers
Roche Holding AG (ISIN CH0012032048, SIX: ROG) ended trading on the SIX Swiss Exchange on September 15, 2026 at 358.40 CHF after intraday losses reported through the day, including a midday quote of 358.40 CHF that was 0.8% below the prior close according to finanzen.ch. Intraday reports showed the share trading around 358.70 CHF to 358.80 CHF later in the afternoon, reflecting continued pressure versus the session open at 359.20 CHF as indicated by finanzen.ch. The broader Swiss market also eased, with the SMI closing at 13,799.44 points, a decline of 0.57% on September 15, 2026 per index data summarized by MarketScreener, meaning Roche’s 0.8% fall slightly underperformed the benchmark.
Cancer study news shapes today’s view
Today, September 16, 2026, attention turns to fresh clinical news after a report that a Roche cancer medicine study extended survival in lung cancer, with the Roche share described as gaining on the back of this study success in a German-language market piece from finanzen.ch. In addition, a Chinese-language update notes that an import application for a Roche antibody injection, Gefitotoximab, was accepted by regulators, highlighting ongoing pipeline activity as reported by Sina Finance. Looking slightly ahead, Roche’s Pharma Day is scheduled for September 28, 2026 in Switzerland, providing another potential catalyst as outlined in a corporate event overview from Ariva, so investors may factor upcoming strategic and pipeline information into their positioning.
